Tag Archives: Cancer

Array’s colorectal cancer data shows why Pfizer splashed out $11B for the biotech

One key incentive for Pfizer paying $ 11 billion for Array BioPharma was the positive early readouts from its triplet therapy for colorectal cancer. Now, the biotech has shown exactly how attractive that data are. A combination of Array’s BRAF inhibitor Braftovi, its MEK inhibitor Mektovi and the anti-EGFR drug Erbitux significantly extended lives of previously-treated patients… Read More »